CIPO Patents = 1 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 4.2

ph-index = 11

Forward Citations = 709(Granted Patents)

Company Filing History:

18 out of 5,450

The University of Texas System

Research Development Foundation

patents

4. 2 out of 5

Board of Trustees, Univ. of Tx Sys.

patents

where one patent can have more than one assignee

Years Active: 1995-2022

Loading Chart...

24 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11236380 - Methods for predicting kinase inhibitor resistance (2022-02-01),

2. 10900059 - Methods for generating engineered enzymes (2021-01-26),

3. 9546359 - Method for engineering proteases and protein kinases (2017-01-17),

4. 8945855 - Method for engineering proteases and protein kinases (2015-02-03),

5. 7902344 - Antibodies with increased affinities for anthrax antigens (2011-03-08),

6. 7871796 - Isolation of binding proteins with high affinity to ligands (2011-01-18),

7. 7611866 - Selection of bacterial inner-membrane anchor polypeptides (2009-11-03),

8. 7446182 - Recombinant antibodies for the detection and neutralization of anthrax toxin (2008-11-04),

9. 7094571 - Combinatorial protein library screening by periplasmic expression (2006-08-22),

10. 7083945 - Isolation of binding proteins with high affinity to ligands (2006-08-01),

11. 6916474 - Antibodies with increased affinities for anthrax antigens (2005-07-12),

12. 6180341 - In vitro scanning saturation mutagenesis of proteins (2001-01-30),

13. 5808059 - Matrix-supported sapphyrins (1998-09-15),

14. 5744302 - Method for separating molecules (1998-04-28),

15. 5672490 - Method of cleaving DNA (1997-09-30),

Title: Brent L Iverson: A Pioneer in Biotechnology and Pharmaceuticals

Introduction:

Brent L Iverson, based in Austin, TX, is a groundbreaking inventor whose passion for innovation and dedication to scientific excellence have made him a prominent figure in the fields of biotechnology and pharmaceuticals.

Latest Patents:

1. Methods for predicting kinase inhibitor resistance: These methods are designed to identify mutant kinases resistant to kinase inhibitors, aiding in the assessment of compounds for potential resistance development during clinical treatment of diseases like cancer.

2. Methods for generating engineered enzymes: Iverson's innovative methods improve the identification of substrate specificity/activity of proteases, convertases, or kinases, including the identification of cleaving patterns within living cells. This involves yeast endoplasmic reticulum sequestration screening and next-generation sequencing.

Career Highlights:

With an impressive 24 patents to his name, Iverson has made significant contributions to the biotechnology and pharmaceutical industries. His work at the University of Texas System and Pharmacyclics, Inc. has been instrumental in advancing scientific knowledge and technological capabilities in drug development.

Collaborations:

Throughout his career, Iverson has collaborated with esteemed colleagues such as Jonathan L Sessler and George Georgiou, further enhancing the impact of his research and inventions in the realm of biotechnology and pharmaceuticals.

Conclusion:

Brent L Iverson's innovative spirit and relentless pursuit of scientific excellence have cemented his status as a pioneering inventor in biotechnology and pharmaceuticals. His contributions continue to shape the future of these industries, inspiring further advancements and breakthroughs in scientific innovation.

This text is generated by artificial intelligence and may not be accurate.